Cargando…

Genomic mapping of copy number variations influencing immune response in breast cancer

Identification of genomic alterations that influence the immune response within the tumor microenvironment is mandatory in order to identify druggable vulnerabilities. In this article, by interrogating public genomic datasets we describe copy number variations (CNV) present in breast cancer (BC) tum...

Descripción completa

Detalles Bibliográficos
Autores principales:	López-Cade, Igor, García-Barberán, Vanesa, Cabañas Morafraile, Esther, Díaz-Tejeiro, Cristina, Saiz-Ladera, Cristina, Sanvicente, Adrián, Pérez Segura, Pedro, Pandiella, Atanasio, Győrffy, Balázs, Ocaña, Alberto
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Frontiers Media S.A. 2022
Materias:	Oncology
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9476651/ https://www.ncbi.nlm.nih.gov/pubmed/36119512 http://dx.doi.org/10.3389/fonc.2022.975437

Ejemplares similares

Mapping Immune Correlates and Surfaceome Genes in BRAF Mutated Colorectal Cancers
por: Morafraile, Esther Cabañas, et al.
Publicado: (2023)

Transcriptomic Mapping of Non-Small Cell Lung Cancer K-RAS p.G12C Mutated Tumors: Identification of Surfaceome Targets and Immunologic Correlates
por: Alcaraz-Sanabria, Ana, et al.
Publicado: (2022)

Mapping of Genomic Vulnerabilities in the Post-Translational Ubiquitination, SUMOylation and Neddylation Machinery in Breast Cancer
por: Fuentes-Antrás, Jesús, et al.
Publicado: (2021)

Transcriptomic Correlates of Immunologic Activation in Head and Neck and Cervical Cancer
por: Saiz-Ladera, Cristina, et al.
Publicado: (2021)

Genomic Mapping of Epidermal Growth Factor Receptor and Mesenchymal–Epithelial Transition-Up-Regulated Tumors Identifies Novel Therapeutic Opportunities
por: Paniagua-Herranz, Lucía, et al.
Publicado: (2023)

Genomic Signatures of Immune Activation Predict Outcome in Advanced Stages of Ovarian Cancer and Basal-Like Breast Tumors
por: Alcaraz-Sanabria, Ana, et al.
Publicado: (2020)

Genomic Correlates of DNA Damage in Breast Cancer Subtypes
por: Cabañas Morafraile, Esther, et al.
Publicado: (2021)

Transcriptomic Profiles of CD47 in Breast Tumors Predict Outcome and Are Associated with Immune Activation
por: Noblejas-López, María del Mar, et al.
Publicado: (2021)

Genomic Mapping of Splicing-Related Genes Identify Amplifications in LSM1, CLNS1A, and ILF2 in Luminal Breast Cancer
por: Noblejas-López, María del Mar, et al.
Publicado: (2021)

Mapping Bromodomains in breast cancer and association with clinical outcome
por: Pérez-Pena, Javier, et al.
Publicado: (2019)

A Transcriptomic Immunologic Signature Predicts Favorable Outcome in Neoadjuvant Chemotherapy Treated Triple Negative Breast Tumors
por: Pérez-Pena, Javier, et al.
Publicado: (2019)

Clinical considerations for the design of PROTACs in cancer
por: Nieto-Jiménez, Cristina, et al.
Publicado: (2022)

Uncovering therapeutic opportunities in the clinical development of antibody‐drug conjugates
por: Nieto‐Jiménez, Cristina, et al.
Publicado: (2023)

Transcriptome evolution from breast epithelial cells to basal-like tumors
por: Santpere, Gabriel, et al.
Publicado: (2017)

Genomic Mapping Identifies Mutations in RYR2 and AHNAK as Associated with Favorable Outcome in Basal-Like Breast Tumors Expressing PD1/PD-L1
por: Cimas, Francisco J., et al.
Publicado: (2020)

BET inhibitors as novel therapeutic agents in breast cancer
por: Ocaña, Alberto, et al.
Publicado: (2017)

Personalized therapies in the cancer "omics" era
por: Ocaña, Alberto, et al.
Publicado: (2010)

Targeting oncogenic vulnerabilities in triple negative breast cancer: biological bases and ongoing clinical studies
por: Ocana, Alberto, et al.
Publicado: (2017)

Proteolysis targeting chimeras (PROTACs) in cancer therapy
por: Ocaña, Alberto, et al.
Publicado: (2020)

Evaluation of transcriptionally regulated genes identifies NCOR1 in hormone receptor negative breast tumors and lung adenocarcinomas as a potential tumor suppressor gene
por: Noblejas-López, María del Mar, et al.
Publicado: (2018)

Neutrophils in cancer: prognostic role and therapeutic strategies
por: Ocana, Alberto, et al.
Publicado: (2017)

Modelling hypersensitivity to trastuzumab defines biomarkers of response in HER2 positive breast cancer
por: Díaz-Gil, Laura, et al.
Publicado: (2021)

Dual targeting of HER2-positive breast cancer with trastuzumab emtansine and pertuzumab: understanding clinical trial results
por: Ocaña, Alberto, et al.
Publicado: (2018)

HER2 heterogeneity and resistance to anti-HER2 antibody-drug conjugates
por: Ocaña, Alberto, et al.
Publicado: (2020)

Novel ADCs and Strategies to Overcome Resistance to Anti-HER2 ADCs
por: Díaz-Rodríguez, Elena, et al.
Publicado: (2021)

Erratum: Achilles' heel of triple negative cancer
por: Ocaña, Alberto, et al.
Publicado: (2014)

Achilles' heel of triple negative cancer
por: Ocaña, Alberto, et al.
Publicado: (2014)

Achilles' heel of triple negative cancer
por: Ocaña, Alberto, et al.
Publicado: (2014)

Breast Cancer Heterogeneity and Response to Novel Therapeutics
por: Baliu-Piqué, Mariona, et al.
Publicado: (2020)

Generation of Antibody-Drug Conjugate Resistant Models
por: Gandullo-Sánchez, Lucía, et al.
Publicado: (2021)

HER3 in cancer: from the bench to the bedside
por: Gandullo-Sánchez, Lucía, et al.
Publicado: (2022)

Genetic mutational status of genes regulating epigenetics: Role of the histone methyltransferase KMT2D in triple negative breast tumors
por: Morcillo-Garcia, Sara, et al.
Publicado: (2019)

Functional transcriptomic annotation and protein–protein interaction analysis identify EZH2 and UBE2C as key upregulated proteins in ovarian cancer
por: Martínez‐Canales, Sandra, et al.
Publicado: (2018)

Transcriptomic immunologic signature associated with favorable clinical outcome in basal-like breast tumors
por: Martínez-Canales, Sandra, et al.
Publicado: (2017)

Mitotic read-out genes confer poor outcome in luminal A breast cancer tumors
por: Pérez-Peña, Javier, et al.
Publicado: (2017)

Identification of therapeutic targets in ovarian cancer through active tyrosine kinase profiling
por: Montero, Juan Carlos, et al.
Publicado: (2015)

Prognostic Value of Lymphocyte-Activation Gene 3 (LAG3) in Cancer: A Meta-Analysis
por: Saleh, Ramy R., et al.
Publicado: (2019)

DNA-damage related genes and clinical outcome in hormone receptor positive breast cancer
por: Nieto-Jiménez, Cristina, et al.
Publicado: (2016)

Antitumoral activity of the mithralog EC-8042 in triple negative breast cancer linked to cell cycle arrest in G2
por: Pandiella, Atanasio, et al.
Publicado: (2015)

Ubiquitin-conjugating enzyme E2T (UBE2T) and denticleless protein homolog (DTL) are linked to poor outcome in breast and lung cancers
por: Perez-Peña, Javier, et al.
Publicado: (2017)

Cannot write session to /tmp/vufind_sessions/sess_vn18t3e98d838moe8782us2fdg